Current and emerging testosterone therapies for male hypogonadism

References

• Bagatell CJ, Bremner WJ. Androgens in men – uses and abuses. N Engl J Med. 1996;334(11):707–714.
   PubMed Web of Science ®Google Scholar
• Jameson JL, De Groot LJ. Endocrinology: Adult and Pediatric. 6th ed. Philadelphia, PA: Saunders; 2010.
   Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, et al; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–2559.
   PubMed Web of Science ®Google Scholar
• Edelstein D, Sivanandy M, Shahani S, Basaria S. The latest options and future agents for treating male hypogonadism. Expert Opin Pharmacother. 2007;8(17):2991–3008.
   PubMed Web of Science ®Google Scholar
• Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724–731.
   PubMed Web of Science ®Google Scholar
• Morley JE, Kaiser FE, Perry HM 3rd, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 1997;46(4):410–413.
   PubMed Web of Science ®Google Scholar
• Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87(2):589–598.
   PubMed Web of Science ®Google Scholar
• Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf). 2006;65(3):275–281.
   PubMed Web of Science ®Google Scholar
• Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241–4247.
   PubMed Web of Science ®Google Scholar
• Werner CA. The Older Population: 2010. 2010 Census Briefs. Washington, DC: US Department of Commerce, Economics and Statistics Administration, US Census Bureau; 2011. Available from: http://www.census.gov/prod/cen2010/briefs/c2010br-09.pdf. Accessed October 9, 2014.
   Google Scholar
• Howden LM, Meyer JA. Age and Sex Composition: 2010. 2010 Census Briefs. Washington, DC: US Department of Commerce, Economics and Statistics Administration, US Census Bureau; 2011. Available from: http://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf. Accessed October 9, 2014.
   Google Scholar
• Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010;64(6):682–696.
   PubMed Web of Science ®Google Scholar
• Basaria S. Male hypogonadism. Lancet. 2014;383(9924):1250–1263.
   PubMed Web of Science ®Google Scholar
• Maggi M, Schulman C, Quinton R, Langham S, Uhl-Hochgraeber K. The burden of testosterone deficiency syndrome in adult men: economic and quality-of-life impact. J Sex Med. 2007;4(4 Pt 1):1056–1069.
   PubMed Web of Science ®Google Scholar
• Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006;166(15):1660–1665.
   PubMedGoogle Scholar
• Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168(6):829–843.
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab. 2005;90(2):712–719.
   PubMed Web of Science ®Google Scholar
• Axelsson J, Ingre M, Akerstedt T, Holmbäck U. Effects of acutely displaced sleep on testosterone. J Clin Endocrinol Metab. 2005;90(8):4530–4535.
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Behre HM, Bouchard P, et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update. 2004;10(5):409–419.
   PubMed Web of Science ®Google Scholar
• Buvat J, Maggi M, Gooren L, et al. Endocrine aspects of male sexual dysfunctions. J Sex Med. 2010;7(4 Pt 2):1627–1656.
   PubMed Web of Science ®Google Scholar
• Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89(5):2085–2098.
   PubMed Web of Science ®Google Scholar
• Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol (Oxf). 2001;54(6):739–750.
   PubMed Web of Science ®Google Scholar
• Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R; North American AA2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003;88(6):2673–2681.
   PubMed Web of Science ®Google Scholar
• Seftel A. Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int J Impot Res. 2007;19(1):2–24.
   Web of Science ®Google Scholar
• Saad F, Gooren LJ, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl. 2008;29(1):102–105.
   PubMedGoogle Scholar
• Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med. 2014;11(6):1567–1576.
   PubMed Web of Science ®Google Scholar
• Wang C, Swerdloff RS, Iranmanesh A, et al; Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839–2853.
   PubMed Web of Science ®Google Scholar
• Pfeil E, Dobs AS. Current and future testosterone delivery systems for treatment of the hypogonadal male. Expert Opin Drug Deliv. 2008;5(4):471–481.
   PubMed Web of Science ®Google Scholar
• Udedibia E, Kaminetsky J. Phase II drugs currently being investigated for the treatment of hypogonadism. Expert Opin Investig Drugs. 2014;23(12):1605–1618.
   PubMed Web of Science ®Google Scholar
• TESTOPEL® (testosterone pellets) [prescribing information]. Rye, NY: Slate Pharmaceuticals, Inc.; 2013.
   Google Scholar
• Kaminetsky JC, Moclair B, Hemani M, Sand M. A phase IV prospective evaluation of the safety and efficacy of extended release testosterone pellets for the treatment of male hypogonadism. J Sex Med. 2011;8(4):1186–1196.
   Web of Science ®Google Scholar
• McCullough AR, Khera M, Goldstein I, Hellstrom WJ, Morgentaler A, Levine LA. A multi-institutional observational study of testosterone levels after testosterone pellet (Testopel®) insertion. J Sex Med. 2012;9(2):594–601.
   Web of Science ®Google Scholar
• Endo Pharmaceuticals. US FDA approves AVEED™ (testosterone undecanoate) injectable testosterone replacement therapy for men living with hypogonadism, or low-T [press release]. Dublin, Ireland: Endo Pharmaceuticals; 2014 [March 6]. Available from: http://www.endo.com/news-events/press-releases. Accessed October 9, 2014.
   Google Scholar
• AVEED® (testosterone undecanoate injection) [prescribing information]. Malvern, PA: Endo Pharmaceuticals; 2014.
   Google Scholar
• Nebido® (1,000 mg/4 mL, solution for injection) [prescribing information]. Leverkusen, Germany: Bayer AG; 2008. Available from: http://www.nebido.com/en/prescribing-information.php. Accessed October 9, 2014.
   Google Scholar
• ANDRIOL® (testosterone undecanoate capsules) [prescribing information]. Kirkland, QC: Merck Canada Inc.; 2011.
   Google Scholar
• ANDRODERM® (testosterone patch) [prescribing information]. Parsippany, NJ: Watson Pharma, Inc.; 2013.
   Google Scholar
• Meikle AW, Arver S, Dobs AS, Sanders SW, Rajaram L, Mazer NA. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site – a clinical research center study. J Clin Endocrinol Metab. 1996;81(5):1832–1840.
   PubMed Web of Science ®Google Scholar
• AndroGel 1.0% (testosterone gel) [prescribing information]. North Chicago, IL: AbbVie Inc.; 2014.
   Google Scholar
• Pope HG Jr, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(1):105–111.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [webpage on the Internet]. Drug approval package: Axiron (testosterone) topical solution, Acrux Pharma Pty Ltd. Silver Spring, MD: US Food and Drug Administration; 2011. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022504_axiron_toc.cfm. Accessed August 15, 2014.
   Google Scholar
• Axiron (testosterone) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; 2014.
   Google Scholar
• Center for Drug Evaluation and Research. Application number: 21-543. Approval letter. Rockville, MD: US Food and Drug Administration; 2003. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-543_Striant_Approv.pdf. Accessed January 13, 2015.
   Google Scholar
• Striant (testosterone buccal tablet) [prescribing information]. Chesterbrook, PA: Actient Pharmaceuticals LLC; 2014.
   Google Scholar
• Department of Health and Human Services. NDA approval letter [Nadesto]. Silver Spring, MD: US Food and Drug Administration; 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/205488Orig1s000ltr.pdf. Accessed January 13, 2015.
   Google Scholar
• Trimel Pharmaceuticals [webpage on the Internet]. Natesto™ (testosterone) nasal gel CIII. Mississauga, ON: Trimel Pharmaceuticals Corporation; 2014. Available from: http://trimelpharmaceuticals.com/Products/Natesto-testosterone-nasal-gel. Accessed August 8, 2014.
   Google Scholar
• Trimel Pharmaceuticals [webpage on the Internet]. TriVair™ nasal gel. Mississauga, ON: Trimel Pharmaceuticals; 2014. Available from: http://trimelpharmaceuticals.com/Technology/Nasal-Gel. Accessed October 9, 2014.
   Google Scholar
• Natesto (testosterone) nasal gel CIII [prescribing information]. Christ Church, Barbados: Trimel BioPharma SRL; 2014.
   Google Scholar
• Antares Pharma, Inc. Antares Pharma announces first patient dosed in phase 3 QuickShot® study evaluating testosterone-deficient adult males [press release]. Ewing, NJ: Antares Pharma, Inc.; 2014 [July 22]. Available from: http://www.antarespharma.com/files/4814/0604/4482/QuickShot_testosterone_first_patient_dosed_P3_study.pdf. Accessed October 9, 2014.
   Google Scholar
• Antares Pharma Inc. Subcutaneous testosterone replacement efficacy and safety in adult men diagnosed with hypogonadism (STEADY). Available from: http://clinicaltrials.gov/ct2/show/NCT02159469?term=antares&rank=7. NLM identifier: NCT02159469. Accessed August 13, 2014.
   Google Scholar
• Antares Pharma, Inc. Antares Pharma announces positive results from the Vibex® Quickshot™ pharmacokinetic study in testosterone deficient men [press release]. Ewing, NJ: Antares Pharma, Inc.; 2014 [February 20]. Available from: http://www.antarespharma.com/files/3314/0000/3220/Testosterone_release_final.pdf. Accessed October 9, 2014.
   Google Scholar
• Antares Pharma, Inc. Antares Pharma announces positive top-line pharmacokinetic results from the Quickshot® phase 3 study in testosterone deficient men [press release]. Ewing, NJ: Antares Pharma, Inc.; 2015 [February 25]. Available from: http://www.antarespharma.com/files/4714/2486/6835/P3_PK_QST__2-24-15.pdf. Accessed February 25, 2015.
   Google Scholar
• Clarus Therapeutics [webpage on the Internet]. Developing a unique oral testosterone therapy. Northbrook, IL: Clarus Therapeutics; 2014. Available from: http://www.clarustherapeutics.com/index.htm. Accessed September 16, 2014.
   Google Scholar
• Lipocine Incorporated [webpage on the Internet]. LPCN 1021. Salt Lake City, UT: Lipocine, Inc.; 2015. Available from: http://lipocine.com/pipeline/lpcn-1021/. Accessed January 13, 2015.
   Google Scholar
• Lipocine Inc. Safety and efficacy of oral LPCN 1021 in men with low testosterone or hypogonadism (SOAR). Available from: http://clinicaltrials.gov/ct2/show/NCT02081300?term=LPCN+1021&rank=1. NLM identifier: NCT02081300. Accessed August 11, 2014.
   Google Scholar
• Clarus Therapeutics, Inc. Clarus Therapeutics reports FDA Advisory Committees vote on REXTORO™ for low testosterone in men [press release]. Northbrook, IL: Clarus Therapeutics, Inc.; 2014 [September 18]. Available from: http://www.clarustherapeutics.com/content/investors-and-media/releases/091814.htm. Accessed December 22, 2014.
   Google Scholar
• Ferring Pharmaceuticals. A clinical trial to evaluate the efficacy and safety of testosterone gel in adult hypogonadal males. Available from: http://clinicaltrials.gov/show/NCT02149264. NLM identifier: NCT02149264. Accessed October 9, 2014.
   Google Scholar
• Olsson H, Sandström R, Neijber A, Carrara D, Grundemar L. Pharmacokinetics and bioavailability of a new testosterone gel in comparison to Testogel® in healthy men. Clinical Pharmacology in Drug Development. 2014;3(5):358–364.
   PubMed Web of Science ®Google Scholar
• Ferring Pharmaceuticals. A clinical trial to evaluate the pharmacokinetics of testosterone gel using an applicator. Available from: http://clinicaltrials.gov/show/NCT01464879. NLM identifier: NCT01464879. Accessed August 19, 2014.
   Google Scholar
• TesoRx Pharma, LLC. TesoRx and CoreRx announce joint venture to manufacture first-in-class oral testosterone drug [press release]. Menlo Park, CA, and Clearwater, FL: TesoRx Pharma, LLC; 2013 [August 28]. Available from: http://www.corerxpharma.com/corerx-blog/corerx-news/tesorx-and-corerx-announce-joint-venture-to-manufacture-first-in-class-oral-testosterone-drug.html. Accessed October 9, 2014.
   Google Scholar
• TesoRx Pharma, LLC. Oral testosterone for the treatment of hypogonadism. Available from: Pharma, LLC. NLM identifier: NCT01717768. Available from: http://clinicaltrials.gov/ct2/show/NCT01717768?term=TSX-002&rank=1. Accessed August 11, 2014.
   Google Scholar
• Powers M. Tesorx crosses all of its ‘T’s’ with $10M series B-1. BioWorld Today. 2014;25(150):1–2.
   Google Scholar
• Transdermal Delivery Solutions Corp. [webpage on the Internet]. Testagen: advancing pro-anabolic science. Palm Beach Gardens, FL: Transdermal Delivery Solutions Corp; 2014. Available from: http://www.tdsc.us/lower.php?url=testagen. Accessed August 15, 2014.
   Google Scholar
• Transdermal Delivery Solutions Corp. A dose ranging study to examine Testagen™ TDS®-testosterone 5% (PARC-T-D). Available from: http://clinicaltrials.gov/ct2/show/NCT01894308?term=testagen&rank=1. NLM identifier: NCT01894308. Accessed August 11, 2014.
   Google Scholar
• Chik Z, Johnston A, Tucker AT, Chew SL, Michaels L, Alam CA. Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males. Br J Clin Pharmacol. 2006;61(3):275–279.
   Web of Science ®Google Scholar
• Muram D. Utilization patterns of parenteral testosterone preparations in hypogonadal men aged at least 45 years: The HIM study. Poster presented at: Endocrine Society’s 96th Annual Meeting; June 22; 2014; Chicago, IL. Poster SUN-0072.
   Google Scholar
• Roska EA, Wilson J. Testosterone prescribing and persistence trends in the department of defense, 2002–2012: A retrospective analysis. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting; April 3, 2014; Tampa, FL. Poster 53.
   Google Scholar
• Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–1836.
   PubMed Web of Science ®Google Scholar
• Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805.
   PubMed Web of Science ®Google Scholar
• Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–122.
   PubMed Web of Science ®Google Scholar
• Raivio T, Santti H, Schatzl G, et al. Reduced circulating androgen bioactivity in patients with prostate cancer. Prostate. 2003;55(3):194–198.
   Web of Science ®Google Scholar
• Kaplan AL, Hu JC. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes. Urology. 2013;82(2):321–326.
   Web of Science ®Google Scholar
• Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2257–2260.
   PubMed Web of Science ®Google Scholar
• Heikkilä R, Aho K, Heliövaara M, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer. 1999;86(2):312–315.
   Web of Science ®Google Scholar
• Morgentaler A. Testosterone replacement therapy and prostate cancer. Urol Clin North Am. 2007;34(4):555–563, vii.
   PubMed Web of Science ®Google Scholar
• Pearl JA, Berhanu D, François N, et al. Testosterone supplementation does not worsen lower urinary tract symptoms. J Urol. 2013;190(5):1828–1833.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [webpage on the Internet]. FDA drug safety communication: FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. Silver Spring, MD: US Food and Drug Administration; 2014. Available from: http://www.fda.gov/drugs/drugsafety/ucm383904.htm. Accessed October 9, 2014.
   Google Scholar
• US Food and Drug Administration. Joint Meeting for Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSARM AC). Silver Spring, MD: US Food and Drug Administration; 2014. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM412536.pdf. Accessed October 8, 2014.
   Google Scholar
• Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels [Erratum]. JAMA. 2014;311(9):967.
   Web of Science ®Google Scholar
• PR Newswire Association LLC [webpage on the Internet]. Twenty-five medical societies join Androgen Study Group to petition JAMA to retract misleading testosterone study. New York, NY: PR Newswire Association LLC; 2014. Available from: http://www.prnewswire.com/news-releases/twenty-five-medical-societies-join-androgen-study-group-to-petition-jama-to-retract-misleading-testosterone-study-254707661.html. Accessed October 9, 2014.
   Google Scholar
• Yeap BB, Hyde Z, Almeida OP, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. J Clin Endocrinol Metab. 2009;94(7):2353–2359.
   PubMed Web of Science ®Google Scholar
• Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol. 2011;58(16):1674–1681.
   PubMed Web of Science ®Google Scholar
• Miner MM, Sadovsky R. Evolving issues in male hypogonadism: evaluation, management, and related comorbidities. Cleve Clin J Med. 2007;74 Suppl 3:S38–S46.
   Google Scholar
• Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005;174(3):827–834.
   PubMed Web of Science ®Google Scholar
• Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2014;68(3):314–329.
   PubMed Web of Science ®Google Scholar
• Baillargeon J, Urban RJ, Kuo YF, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48(9):1138–1144.
   PubMed Web of Science ®Google Scholar
• Ruige JB, Ouwens DM, Kaufman JM. Beneficial and adverse effects of testosterone on the cardiovascular system in men. J Clin Endocrinol Metab. 2013;98(11):4300–4310.
   PubMed Web of Science ®Google Scholar
• Kacker R, Traish AM, Morgentaler A. Estrogens in men: clinical implications for sexual function and the treatment of testosterone deficiency. J Sex Med. 2012;9(6):1681–1696.
   PubMed Web of Science ®Google Scholar
• DEPO® testosterone CIII (testosterone cypionate injection, USP) [prescribing information]. New York, NY: Pfizer Inc.; 2014.
   Google Scholar
• AndroGel® 1.62% (testosterone gel) [prescribing information]. North Chicago, IL: AbbVie Inc.; 2014.
   Google Scholar
• FORTESTA® (testosterone) gel for topical use CIII [prescribing information]. Malvern, PA: Endo Pharmaceuticals Inc.; 2014.
   Google Scholar
• Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560–2575.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90(8):871–876.
   PubMed Web of Science ®Google Scholar
• Carson CC 3rd, Rosano G. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med. 2012;9(1):54–67.
   Web of Science ®Google Scholar
• Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH, Channer K. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009;161(3):443–449.
   PubMed Web of Science ®Google Scholar
• English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102(16):1906–1911.
   PubMed Web of Science ®Google Scholar
• Oskui PM, French WJ, Herring MJ, Mayeda GS, Burstein S, Kloner RA. Testosterone and the cardiovascular system: a comprehensive review of the clinical literature. J Am Heart Assoc. 2013;2(6):e000272.
   Web of Science ®Google Scholar